Claire Gallois, Qian Shi, Levi D Pederson, Thierry André, Timothy J Iveson, Alberto F Sobrero, Steven Alberts, Aimery de Gramont, Jeffrey A Meyerhardt, Thomas George, Hans-Joachim E Schmoll, Ioannis Souglakos, Andrea Harkin, Roberto Labianca, Frank A Sinicrope, Eiji Oki, Anthony F Shields, Ioannis Boukovinas, Rachel Kerr, Sara Lonardi, Greg Yothers, Takayuki Yoshino, Richard M Goldberg, Julien Taieb, Demetris Papamichael
PURPOSE: A number of studies suggest that older patients may have reduced or no benefit from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon cancer (CC). MATERIALS AND METHODS: We studied the prognostic impact of age, as well as treatment adherence/toxicity patterns according to age, in patients with stage III CC who received 3 or 6 months of infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (CAPOX) on the basis of data collected from trials from the ACCENT and IDEA databases...
March 28, 2024: Journal of Clinical Oncology